Skip to main content
SpringerLink
Log in

The Genetics of Triple-Negative Breast Cancer

  • Chapter
  • First Online:
Triple-Negative Breast Cancer

  • 1556 Accesses

Abstract

With the advent of next generation sequencing, understanding genetic susceptibility to triple-negative breast cancer (TNBC) can lead to the identification, screening, and management of at-risk individuals and improved outcomes for those affected with this disease. The most commonly involved cancer susceptibility genes in TNBC are BRCA1 and BRCA2. Intense screening strategies have proven to identify affected cases, and risk-reducing surgical procedures have been shown to decrease the likelihood of developing cancer. Treatment of advanced TNBC remains a challenge. More emphasis should be placed on defining the genetic risk factors of TNBC which can ultimately lead to comprehensive efforts focused on cancer risk assessment and prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.

    Article  CAS  PubMed  Google Scholar 

  2. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265:2088–90.

    Article  CAS  PubMed  Google Scholar 

  3. Li X, Heyer WD. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008;18:99–113.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–16.

    Article  CAS  PubMed  Google Scholar 

  5. Lee E, McKean-Cowdin R, Ma H, et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 2011;29:4373–80.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26:4282–8.

    Article  PubMed  Google Scholar 

  7. Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21:134–47.

    Article  CAS  PubMed  Google Scholar 

  8. Tun NM, Villani G, Ong K, et al. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clin Genet. 2014;85:43–8.

    Article  CAS  PubMed  Google Scholar 

  9. Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Evans DG, Howell A, Ward D, et al. Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet. 2011;48:520–2.

    Article  CAS  PubMed  Google Scholar 

  11. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33:304–11.

    Article  CAS  PubMed  Google Scholar 

  12. Fostira F, Tsitlaidou M, Papadimitriou C, et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat. 2012;134:353–62.

    Article  CAS  PubMed  Google Scholar 

  13. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Rummel S, Varner E, Shriver CD, et al. Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. Breast Cancer Res Treat. 2013;137:119–25.

    Article  PubMed  Google Scholar 

  15. Greenup R, Buchanan A, Lorizio W, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20:3254–8.

    Article  PubMed  Google Scholar 

  16. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401–8.

    Article  CAS  PubMed  Google Scholar 

  17. Comen E, Davids M, Kirchhoff T, et al. Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women. Breast Cancer Res Treat. 2011;129:185–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kurian AW, Fish K, Shema SJ, et al. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res. 2010;12:R99.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009;27:4515–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Fackenthal JD, Zhang J, Zhang B, et al. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012;131:1114–23.

    Article  CAS  PubMed  Google Scholar 

  21. Churpek JE, Walsh T, Zheng Y, et al. Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2015;149:31–9.

    Article  CAS  PubMed  Google Scholar 

  22. Daly MB, Pilarski R, Axilbund JE, et al. Genetic/familial high-risk assessment: breast and ovarian, version 2.2015. J Natl Compr Canc Netw. 2016;14:153–62.

    Article  PubMed  Google Scholar 

  23. Masciari S, Dillon DA, Rath M, et al. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat. 2012;133:1125–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hwang SJ, Lozano G, Amos CI, et al. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003;72:975–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Figueiredo BC, Sandrini R, Zambetti GP, et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet. 2006;43:91–6.

    Article  CAS  PubMed  Google Scholar 

  26. Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy Statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015;33:3660–7.

    Article  CAS  PubMed  Google Scholar 

  27. Berliner JL, Fay AM, Cummings SA, et al. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns. 2013;22:155–63.

    Article  PubMed  Google Scholar 

  28. Weitzel JN, Blazer KR, MacDonald DJ, et al. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin. 2011;61:327–59.

    PubMed  PubMed Central  Google Scholar 

  29. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111–30.

    Article  PubMed  Google Scholar 

  30. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317–25.

    Article  CAS  PubMed  Google Scholar 

  31. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427–37.

    Article  CAS  PubMed  Google Scholar 

  32. Lehman CD, Lee JM, DeMartini WB, et al. Screening MRI in women with a personal history of breast cancer. J Natl Cancer Inst. 2016;108. pii: djv373.

    Google Scholar 

  33. Li X, You R, Wang X, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res. 2016;22:3971–81.

    Article  CAS  PubMed  Google Scholar 

  34. Evans DG, Gaarenstroom KN, Stirling D, et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet. 2009;46:593–7.

    Article  CAS  PubMed  Google Scholar 

  35. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26:1331–7.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Irvin WJ Jr, Carey LA. What is triple-negative breast cancer? Eur J Cancer. 2008;44:2799–805.

    Article  CAS  PubMed  Google Scholar 

  38. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.

    Article  CAS  PubMed  Google Scholar 

  39. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA

    Nanna H. Sulai MD

  2. Department of Internal Medicine, Division of Hematology Oncology, University of Chicago Medical Center, Chicago, IL, USA

    Olufunmilayo I. Olopade MD, FACP

Authors
  1. Nanna H. Sulai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olufunmilayo I. Olopade MD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nanna H. Sulai MD .

Editor information

Editors and Affiliations

  1. Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, USA

    Antoinette R. Tan

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sulai, N.H., Olopade, O.I. (2018). The Genetics of Triple-Negative Breast Cancer. In: Tan, A. (eds) Triple-Negative Breast Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-69980-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-69980-6_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-69979-0

  • Online ISBN: 978-3-319-69980-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation